In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cancer Genetics (NASDAQ: CGIX), with a price target of $3. The company’s shares closed yesterday at $0.99, close to its 52-week low of $0.82.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -2.9% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cancer Genetics with a $3 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.75 and a one-year low of $0.82. Currently, Cancer Genetics has an average volume of 108.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.
